Update on Kawasaki disease in Hong Kong
Y W Cheng 鄭恩華, L M Wong 黃立明, K T So 蘇鈞堂
HK Pract 2003;25:127-133
Summary
Kawasaki disease is an important diagnosis to be considered when seeing a child with
fever. It carries important, severe and long-term morbidity if it is missed or if
intravenous gamma-globulin (IVGG) is not given before the tenth day of illness.
Family physicians should be familiar with the diagnostic criteria of this common
disease. They play an important role in identifying, referring and managing patients
with Kawasaki disease. This article aims to highlight the diagnosis and to give
an update on the aetiology of Kawasaki disease.
摘要
小兒發燒,要考慮川崎症這個重要的疾病。漏診 或者沒有在發病十天內給予靜脈注射丙種球蛋白(IVGG),可引起嚴重後果。 家庭醫生應熟悉此病的診斷標准,他們可以對此症的辨認,轉介和治療起極大作用。
本文旨在分享診斷以及提供有關川崎症病因的最新資料。
Introduction
In the pre-antibiotic era, rheumatic heart disease was the most common paediatric
acquired heart disease. Nowadays, general practitioners or paediatricians in Hong
Kong seldom come across a case of rheumatic heart disease in their daily practice.
In the hospital setting, new paediatric immigrants from China still contribute a
few cases of chronic rheumatic heart disease every year. Prolonged fever in an infant,
heart murmur in a child and chest pain in an adolescent patient are less likely
to be caused by rheumatic heart disease but they may mean another important acquired
heart disease, Kawasaki disease.
Kawasaki disease has silently emerged as the most common acquired heart disease
in paediatric patients in Hong Kong. It has become a challenge for researchers to
find out the aetiology and more definitive treatment for this group of patients.
It is important to make a prompt diagnosis and start treatment without delay in
order to prevent serious cardiovascular complications.
History
Dr Kawasaki T, a Japanese paediatrician, first described this disease in 1967. He
reported 50 children who presented from 1961 to 1967 with prolonged fever and discrete
clinical signs/symptoms. He termed the disease mucocutaneous lymph node syndrome
and finally named it as Kawasaki disease or Kawasaki syndrome.1 It was
thought to be a benign disease until late 1970, 10 children with the disease died
because of the coronary complications which aroused the alertness of the world about
it.2
Local incidence
According to the 6 year surveillance study of the Hong Kong Kawasaki Disease Study
Group, the incidence was 31.2 per 100,000 children aged below 5 and the male to
female ratio was 1.63.3
Diagnosis (Table 1)
There are no definitive diagnostic tests for Kawasaki disease and the diagnosis
is based on clinical features. For a diagnosis to be made, a patient has to fulfill
three criteria:4
Figure 1: Bilateral non-suppurative conjunctival
injection
|
|
|
|
Figure 2: Changes of oral mucosa: erythematous,
dry and fissured lips
|
|
|
Figure 3: Polymorphous skin rash over the trunk
|
|
|
|
Figure 4: Peri-ungal desquamation
|
|
|
|
Criterion a:
|
|
|
Fever lasting for 5 days or more.
|
|
|
Criterion b:
|
|
|
4 out of 5 of the following features:
|
|
|
i.
|
Bilateral non-suppurative conjunctival injection.
|
|
|
ii.
|
Changes of oral mucosa: erythematous, dry and fissured lips; strawberry
tongue.
|
|
|
iii.
|
Changes of hands and feet: erythema with or without edema, later peri-ungual
desquamation.
|
|
|
iv.
|
Polymorphous skin rash: mainly on the trunk, may be maculo-papular or erythema
multiforme.
|
|
|
v.
|
Cervical lymphadenopathy: node diameter greater than 1.5cm
|
|
|
Criterion c:
|
|
|
Illness cannot be explained by other known conditions.
|
|
Other features including arthralgia, arthritis, diarrhoea, otitis media are quite
non-specific but are commonly encountered in patients with Kawasaki disease. Investigations
such as chest x-ray may show pneumonitis and ultrasonography may detect acute distension
(hydrops) of the gallbladder. These are also common.5
Practical hints
From my personal experience, most patients with Kawasaki disease are toddlers presenting
with fever, minimal cough or runny nose (skin
rashes). Most (or nearly all) children with Kawasaki disease are very irritable
and I personally have not seen a comfortable child. Irritability is very commonly
seen in infants with Kawasaki disease and it may be due to the aseptic meningitis.
Moreover, fever in Kawasaki disease is usually above the baseline (normal) body
temperature despite regular panadol treatment in contrast to the fever pattern due
to upper respiratory tract infection which is usually swinging, on and off as described
by most parents.
Erythema at the site of Calmette-Guerin bacillus (BCG) inoculation is rare but it
is a rather specific sign of Kawasaki disease.6,7 We have diagnosed two
children early by looking at the BCG scar on admission.
Erythrocyte sedimentation rate (ESR) is usually increased in patients with Kawasaki
disease. Although non-specific, it may be helpful in the general practice setting
in diagnosing this disease.
The platelet counts are usually normal until one to two weeks from the onset of
the disease.
In conclusion, you should consider referring an irritable child with fever for more
than 5 days who did not respond to anti-pyretics and with skin rashes
conjunctivitis for further evaluation.
Echocardiogram may sometimes assist in making the diagnosis of Kawasaki disease
in the hospital setting.
Treatment
Intravenous gamma-globulin (IVGG) and aspirin are the standard treatment for all
cases of Kawasaki disease admitted to hospital, under the Hospital Authority in
Hong Kong, within 10 days of diagnosis since 2001.8 Treatment in the
first 10 days of illness with a single dose of IVGG, 2 grams per kg body weight
and high dose (anti-inflammatory) aspirin of 80 to 100mg per kg body weight per
day, reduces the prevalence of coronary abnormalities from 20-25% to 2-4%.9-11
A second dose of IVGG may be needed if fever has not subsided. Aspirin will be changed
to a lower dose (anti-thrombotic) when fever has subsided and is usually maintained
until 8 weeks after the onset of the disease or resolution of the coronary aneurysm.
Outcome
For Kawasaki disease, studies have found that patients with regression of the coronary
artery aneurysm (CAA) still demonstrated various degrees of intimal thickening by
intra-vascular ultrasound. There was more vascular constriction with acetylcholine
and poorer dilatation with isosorbide dinitrate. These results suggest that regressed
CAA might have endothelial dysfunction with impaired endothelium dependent vasodilatation.
In addition, they might have smooth muscle dysfunction with impaired response to
isosorbide dinitrate.12 In my opinion, these patients should be followed
up further for development of premature atherosclerosis. Until more definitive clinical
outcomes are available, it is advisable for them to avoid risk factors for atherosclerosis
e.g. smoking, obesity, hypertension and hyperchole-sterolaemia.
Follow-up
It is out of the scope of this article to discuss the long-term management of Kawasaki
disease but I would like to share our data and experience of our patients with Kawasaki
disease. Most paediatric cardiologists in Hong Kong manage and follow-up the cases
based on the risk stratification approach published by the committee on rheumatic
fever, endocarditis and Kawasaki disease, the Council on cardiovascular disease
in the Young, American Heart Association.13
In our hospital, we have a new case diagnosed per month on average. We have 65 patients
with history of Kawasaki disease currently being followed-up in our clinic. Neither
an epidemic nor a seasonal cluster has been observed. There are 42 male patients
with male to female ratio of 1.8:1.0. The mean age at diagnosis was 1.6 years of
age (median age 1.2 years). Seven out of the 65 patients had biochemical evidence
of hepatitis with raised alanine aminotransferase (ALT) but all of them were transient.
Transient coronary dilatations or ectasia of the arterial wall were commonly observed,
about one third during the acute disease. But long-term complications are rare in
our series (5%). One out of five patients (20%) who did not receive IVGG treatment
developed coronary complications. For those 60 patients who received IVGG treatment,
three of them (5%) still developed coronary complications with bilateral saccular
type aneurysms requiring long-term aspirin treatment and close follow-up and monitoring.
Advances in Kawasaki disease
Despite advances in culture technique, intensive investigation and extensive research,
the aetiology of Kawasaki disease remains unknown. Recent research propose super-antigen
as the most likely aetiology for the condition. In order to understand what is super-antigen,
one should know the different immune responses triggered by conventional antigen
and by super-antigen.
Super-antigen
Conventional antigen elicits an immune response only after being ingested by an
antigen-presenting cell and it expresses on the surface of the cell within a specific
antigen-binding site formed by major histocompatibility complex (MHC) class II molecules.
Limited number and specific type of lymphocytes will be activated.
In contrast, superantigens bind themselves to MHC class II molecules on the surface
of the antigen-presenting cell without becoming ingested and at the site outside
the classical binding site. The MHC-bound superantigen interacts with a T-cell receptor
(TCR) by means of a variable portion of the beta-chain. All T-cells possessing a
specific sequence on the TC receptor (V beta 2 T-cell) are activated by the MHC-superantigen
complex, and this can activate as many as 20% of the circulating lymphocytes.17
The release of large amounts of cytokines produces a wide involvement of different
organ inside the body.18
The most recently proposed aetiologic candidate has been a superantigen named toxic
shock syndrome toxin-1 (TSST-1). Recent studies indicating that certain families
of T-cell receptor (beta) genes (V [beta] 2 and V [beta] 8) were preferentially
expressed in the peripheral blood lymphocytes of patients with Kawasaki disease.19-21
The clinical features of Kawasaki disease which are similar to those seen in patients
with staphylococcal and streptococcal toxin-mediated disease can also be explained
by this superantigen theory.
There is also evidence showing that different toxin concentrations elicit different
immune responses and it provides an explanation why some patients with Kawasaki
disease did not have full-blown features of Kawasaki disease.
Important practical points for the general practitioner
It is also important to advise discontinuation of aspirin for two weeks to avoid
the risk for Reyes' syndrome for patients having contact with chickenpox.22,23
Aspirin may be replaced temporarily by another anti-platelet agents, such as dipyridamole
(2-3mg/kg/does, three times per day) for patients with high risk of thrombosis.
Concerning vaccination, administration of live vaccines (i.e. measles, mumps, rubella,
and varicella) should be delayed for 6 months after IVGG because antibodies may
interfere with the immune responses to the vaccines.24
Conclusion
Kawasaki disease is the most common acquired paediatric heart disease in Hong Kong,
which carries important, severe and long-term morbidity, particularly if IVGG was
not given before the tenth day of illness. Family physicians play an important role
in identifying the cases and referring them for IVGG treatment. It is also important
to stop aspirin for Kawasaki patients who contact chickenpox. Vaccination with live
vaccine should be delayed if indicated. Advice should also be given to patients
to avoid risk factors for atherosclerosis e.g. smoking, obesity, hypertension and
hyperchole-sterolaemia.
The most recently proposed aetiologic candidate for Kawasaki disease has been the
super-antigen. Hopefully, further research along this line may find out the definitive
aetiology and treatment for this mysterious disease.
Key messages
- Kawasaki disease (KD) is the most common acquired paediatric heart disease in Hong
Kong.
- Cervical lymph node is the least common sign in KD and is absent in about half of
the patients and infant with KD.
- Reactivation of BCG scar is said to be a specific sign of KD.
- Intravenous gamma globulin (IVGG) given before the 10th day of illness greatly reduces
the prevalence of coronary aneurysm. It is important not to delay referring patient
when KD is suspected.
- Patients on aspirin should be advised to stop the drug for two weeks if they have
contact with chickenpox to avoid the possibility of Reye syndrome.
- Vaccinations with live vaccine should be delayed for 6 months after IVGG treatment.
Y W Cheng, MBChB(CUHK), DCH(Ire, Int), MRCP(UK)
Medical Officer,
L M Wong, MRCP(UK), FHKAM(Paediatrics)
Medical Officer,
K T So, FRCP(Edin, Glasg), FHKAM(Paediatrics)
Chief of Service,
Department of Paediatrics and Adolescent Medicine, Tuen Mun Hospital.
Correspondence to : Dr Y W Cheng, Department of Paediatrics and Adolescent
Medicine, Tuen Mun Hospital, Tuen Mun, NT, Hong Kong.
References
- Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with
specific desquamation of the fingers and toes in children. Clinical observation
of 50 patients. Jpn J Allergy 1967;16:178-222.
- Kato H, Koike S, Yamamoto M, et al. Coronary aneurysms in infants and young children
with acute febrile mucocutaneous lymph node syndrome. J Paediatr 1975;86:892-898.
- Ng YM, Sung R, So LY, et al. A 6-year surveillance of Kawasaki disease in Hong Kong.
Hong Kong Kawasaki Disease Study Group, 2001.
- Shulman ST, Bass JL, Bierman F, et al. Management of Kawasaki syndrome: a consensus
statement prepared by North American participants of the third International Kawasaki
disease symposium, Tokyo, Japan, December, 1988. Paediatr Infect Dis J 1989;8:663-665.
- Tizard EJ, Suzuki A, Levin M, et al. Clinical aspects of 100 patients with Kawasaki
disease. Arch Dis Child 1991;66:185-188.
- Plantin P, Blayo M, Dupre D, et al. BCG reactivation: a rare but specific sign of
Kawasaki disease. Presse Med 1998 Apr 18;27(15):716.
- Yokota S, Tsubaki K, Kuriyama T, et al. Presence in Kawasaki disease of antibodies
to mycobacterial heat-shock protein HSP65 and autoantibodies to epitopes of human
HSP65 cognate antigen. Clin Immunol Immunopathol 1993 May;67(2):163-170.
- Yung TC, So LY, Ho HK, et al. Clinical Guideline on the use of intravenous gammaglobulin
in children with Kawasaki disease: prevention or coronary artery lesions. 5:2001.
- Shulman ST, Inocencio J, Hirsch R. Kawasaki disease. Paediatr Clin North Am 1995;42:1205-1222.
- Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease
is highly dependent on gamma globulin dose but independent of salicylate dose. J
Paediatr 1997;131:888-893.
- Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery
aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin
treatment. Paediatrics 1995;96:1057-1061.
- Iemura M, Ishii T, Sugimura T, et al. Long term consequences of regressed coronary
aneurysms after Kawasaki disease: vascular wall morphology and function. Heart 2000;83:307-311.
- Adnan S Dajani, et al. Report from the committee on rheumatic fever, endocarditis,
and Kawasaki disease, council on cardiovascular disease in the Young, American Heart
Association. Guidelines for long-term management of patients with Kawasaki disease.
Circulation 1994;89:916-922.
- Tsuchida S, Yamanaka T, Tsuchida R, et al. Epidemiology of infant Kawasaki disease
with a report of the youngest neonatal case ever reported in Japan. Acta Paediatr
1996;85:995-997.
- Yanagawa H, Yashiro M, Nakamura Y, et al. Results of 12 nation-wide epidemiological
incidence survey of Kawasaki disease in Japan. Arch Paediatr Adolesc Med 1995;149:779-783.
- Fujita Y, Nakamura Y, Sakata K, et al. Kawasaki disease in families. Paediatrics
1989;84:666-669.
- Yamashiro Y, Nagata S, Oguchi S, et al. Selective increase of V beta 2 T cells in
the small intestine mucosa in Kawasaki disease. Paediatr Res 1996;39:264-266.
- Curtis N, Zheng R, Lamb JR, et al. Evidence for a superantigen mediated process
in Kawasaki disease. Arch Dis Child 1995;72:308-311.
- Yoshioka T, Matsutani T, Iwagami S, et al. Polycloncal expansion of TCRBV2- and
TCRBV6-bearing T cells in patients with Kawasaki disease. Immunology 1999;96:465-472.
- Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science
1990;248:705-711.
- Leung DYM, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus
aureus in Kawasaki syndrome. Lancet 1993;342:1385-1388.
- Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of one case.
Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1992 Jan-Feb;33(1):67-71.
- Takahashi M, Mason W. Kawasaki syndrome, Reye syndrome, and aspirin. Paediatrics
1986;77(4):616-617.
- Salisbury DM, Begg NT, eds. Immunisation against infectious disease. London: HMSO,
1996:24.
|